BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 6831434)

  • 1. Predictive values of the in vivo diffusion chamber for cyclophosphamide treatment of L1210 murine leukemia.
    Anderson KC; Humphrey RL; Sensenbrenner LL
    Cancer Res; 1983 May; 43(5):2030-3. PubMed ID: 6831434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
    Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
    Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
    Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
    Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of recombinant human tumor necrosis factor-alpha, alone and in combination with cyclophosphamide or methotrexate, on leukemia L1210 and normal hematopoiesis in mice.
    Warzocha K; Robak T; Korycka A; Graczyk J; Pakulska W; Gałazka G; Kłysik J
    Arch Immunol Ther Exp (Warsz); 1991; 39(5-6):587-95. PubMed ID: 1841555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice.
    Warzocha K; Robak T
    Acta Haematol Pol; 1992; 23(1):55-62. PubMed ID: 1615753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
    Avery TL; Roberts D
    Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo DNA cross-linking by cyclophosphamide: comparison of human chronic lymphatic leukemia cells with mouse L1210 leukemia and normal bone marrow cells.
    DeNeve W; Valeriote F; Edelstein M; Everett C; Bischoff M
    Cancer Res; 1989 Jul; 49(13):3452-6. PubMed ID: 2731167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoimmunotherapy of L1210 leukemia with adriamycin, cyclophosphamide, and OK-432, and their effects on the generation of antitumor immunity.
    Ujiie T
    Jpn J Cancer Res; 1987 Jul; 78(7):737-47. PubMed ID: 3114200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of 2-chloro-2'-deoxyadenosine alone and in combination with cyclophosphamide or methotrexate on murine leukemia L1210.
    Góra-Tybor J; Robak T; Warzocha K; Grieb P
    Arch Immunol Ther Exp (Warsz); 1994; 42(1):39-42. PubMed ID: 7503633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined therapy of L1210 leukemia with cyclophosphamide and lycurim.
    Stoychkov JN; Milushev AS; Todorov DK
    Neoplasma; 1980; 27(1):33-6. PubMed ID: 6892839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388.
    Góra-Tybor J; Robak T
    Acta Haematol Pol; 1993; 24(2):177-82. PubMed ID: 8103959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy involving alpha-difluoromethylornithine and 1-beta-D-arabinofuranosylcytosine in murine L1210 leukemia.
    Prakash NJ; Sunkara PS
    Cancer Res; 1983 Jul; 43(7):3192-6. PubMed ID: 6406054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedule-dependency assessments of ribonucleoside diphosphate reductase inhibitors when used in combination with platinum compounds plus cyclophosphamide in the treatment of advanced L1210 leukemia.
    Gale GR; Atkins LM; Meischen SJ; Schwartz P
    Cancer Treat Rep; 1979 Mar; 63(3):449-56. PubMed ID: 427825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of immune resistance against L1210 lymphatic leukemia in mice after chemoradiotherapy of the leukemia and reconstitution with bone marrow purged from the leukemia with mafosfamide.
    Skórski T; Kawalec M
    Exp Hematol; 1988 Oct; 16(9):782-4. PubMed ID: 3049130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of a water-insoluble compound entrapped in liposomes on L1210 leukemia in mice.
    Brassinne C; Atassi G; Frühling J; Penasse W; Coune A; Hildebrand J; Ruysschaert JM; Laduron C
    J Natl Cancer Inst; 1983 Jun; 70(6):1081-6. PubMed ID: 6574278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy of advanced L1210 leukemia with platinum compounds in combination with other antitumor agents.
    Gale GR; Atkins LM; Meischen SJ; Smith AB; Walker EM
    Cancer Treat Rep; 1977; 61(3):445-50. PubMed ID: 872142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil.
    Klubes P; Cerna I
    Cancer Res; 1983 Jul; 43(7):3182-6. PubMed ID: 6850628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experiment to potentiate the effect of cyclophosphamide combined with tempidon and caffeine in leukemia L1210 and Lewis hepatic carcinoma].
    Stoichkov I; Milushev A; Todorov D
    Eksp Med Morfol; 1978; 17(1):9-14. PubMed ID: 639751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electronic volume analysis of L1210 chemotherapy.
    Zucker RM; Helfman D
    Cancer Res; 1976 Dec; 36(12):4434-8. PubMed ID: 1000492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue pharmacokinetics, inhibition of DNA synthesis and tumor cell kill after high-dose methotrexate in murine tumor models.
    Sirotnak FM; Donsbach RC; Dorick DM; Moccio DM
    Cancer Res; 1976 Dec; 36(12):4672-8. PubMed ID: 1000510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.